OncoMatch/Clinical Trials/NCT06712355
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Is NCT06712355 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Pumitamig and Atezolizumab for extensive-stage small-cell lung cancer.
Treatment: Pumitamig · Atezolizumab · Etoposide · Carboplatin (or cisplatin if carboplatin is not tolerated) — This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage AJCC 8TH EDITION STAGE IV (T ANY, N ANY, M1A/B/C), T3~4 FOR MULTIPLE LUNG NODULES OR TUMOR/NODULE VOLUME THAT CANNOT BE ENCOMPASSED IN A TOLERABLE RADIOTHERAPY PLAN (AJCC 8th edition, VALG)
Metastatic disease required
AJCC 8th edition stage IV (T any, N any, M1a/b/c), or T3~4 for multiple lung nodules or tumor/nodule volume that cannot be encompassed in a tolerable radiotherapy plan
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: Participants with prior chemoradiotherapy for limited-stage-SCLC must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible.
Have not had prior systemic therapy for ES-SCLC. However, participants with prior chemoradiotherapy for limited-stage-SCLC must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible.
Cannot have received: anti-VEGF monoclonal antibody
Have received prior treatment with anti-vascular endothelial growth factor (VEGF) monoclonal antibody
Cannot have received: PD-L1/VEGF bispecific antibody
Have received prior treatment with programmed death (ligand)-1 (PD[L]-1)/VEGF bispecific antibody
Lab requirements
Blood counts
Adequate hematologic and organ function as defined in the protocol
Kidney function
Adequate hematologic and organ function as defined in the protocol
Liver function
Adequate hematologic and organ function as defined in the protocol
Adequate hematologic and organ function as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clermont Oncology Center · Clermont, Florida
- Cancer Care Centers of Brevard, Inc · Palm Bay, Florida
- Illinois Cancer Specialists · Niles, Illinois
- Fort Wayne Medical Oncology and Hematology, Inc · Fort Wayne, Indiana
- McFarland Clinic · Ames, Iowa
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify